Completed Studies

Completed accrual studies

No.

Participated Studies

Total Accrual No.

TALCC Accrual No.

1

INTACT-1: Randomized, double-blind, phase III comparative trial of two doses of ZD1839 (gefitinib) in combination with gemcitabine and cisplatin versus placebo in combination with gemcitabine and cisplatin in chemotherapy-naive patients with advanced (stage III or IV) NSCLC.

1093

40

2

JMEI: Phase III trial of pemetrexed versus docetaxel in patients with locally advanced or metastatic NSCLC who were previously treated with chemotherapy.

566

51

3

Phase III trial of LY900003 plus gemcitabine and cisplatin versus gemcitabine and cisplatin in patient with advanced, previous untreated NSCLC.

676

62

4

FASTACT-I: Phase II, randomized, double-blind trial of sequential erlotinib and chemotherapy as first-line treatment in patients with stage IIIB/IV NSCLC.

154

22

5

TALENT: Randomized, double-blind, placebo-controlled, multicenter, phase III study of erlotinib plus chemotherapy (cisplatin and gemcitabine) versus chemotherapy alone in patients with advanced (stage IIIB or IV) NSCLC who have not received prior chemotherapy.

1172

9

6

ISEL: ZD1839 (gefitinib) versus placebo as 2nd or 3rd-line salvage therapy in patients with advanced NSCLC.

1692

110

7

S037: Open-label, single-arm, phase II study of pemetrexed in patients with advanced NSCLC who have had prior chemotherapy.

186

46

8

INVITE: Randomized, open-label, parallel group, multicenter, phase II study of progression free survival comparing ZD1839 (gefitinib) versus vinorelbine in chemonaive elderly patient with locally advanced (stage IIIB) or metastatic (stage IV) NSCLC.

196

11

9

JMDB: Pemetrexed and cisplatin versus gemcitabine and cisplatin in patients with locally advanced or metastatic NSCLC.

1713

71

10

FLEX: Cetuximab in combination with cisplatin-based chemotherapy versus cisplatin-based chemotherapy alone as first-line treatment for patient with EGFR-expressing advanced NSCLC.

1125

43

11

JMEN: Phase III, double-blind, placebo-controlled study of maintenance pemetrexed versus best supportive care immediately following induction treatment for advanced NSCLC.

673

9

12

IPASS: Open-label, randomized, parallel group, multicenter, phase III study to assess efficacy, safety and tolerability of gefitinib versus carboplatin/paclitaxel doublet chemotherapy as first-line treatment in selected patients with advanced (stage IIIB or IV) NSCLC in Asia.

1217

131

13

SAiL: Open-label study of bevacizumab in combination with platinum-containing chemotherapy as first-line treatment of patients with advanced or recurrent non-squamous NSCLC.

2055

50

14

BeTa: Phase III, multicenter, placebo-controlled, double-blind, randomized clinical trial to evaluate the efficacy of bevacizumab in combination with erlotinib compared with erlotinib alone for treatment of advanced NSCLC after failure of standard first-line chemotherapy.

636

12

15

ATLAS: Randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib after completion of chemotherapy with bevacizumab for the first-line treatment of locally advanced recurrent or metastatic NSCLC.

1150

planned

 

16

LUX-LUNG-2: Phase II, single-arm trial of BIBW 2992 in NSCLC patients with EGFR activating mutations.

104

planned

 

17

MISSION: Phase III, placebo-controlled trial of sorafenib (BAY43-9006) in patients with relapsed or refractory advanced NSCLC.

700

planned

 

18

FASTACT-II: Randomized, placebo-controlled, double-blind, phase II study of sequential administration of erlotinib or placebo in combination with gemcitabine/platinum as first-line treatment in patients with stage IIIB/IV NSCLC.

450

planned

 

19

LUX-LUNG-1: Phase IIb/III, randomized, double-blind trial of BIBW 2992 versus placebo in NSCLC patients failing erlotinib or gefitinib.

585

planned

123

20

LUX-LUNG-3: Randomized, open-label, phase III study of BIBW 2992 versus chemotherapy as first-line treatment for patients with stage IIIB or IV adenocarcinoma of the lung harboring an EGFR activating mutation.

330 planned

 

21

P06162: Phase Ib/II study of SCH 900105 in combination with gefitinib in Asian subjects with NSCLC.

188

planned

 

22

A8081007: Phase III, randomized, open-label study of the efficacy and safety of PF-02341066 versus standard of care chemotherapy (pemetrexed or docetaxel) in patients with advanced NSCLC harboring a translocation or inversion involving the anaplastic lymphoma kinase (ALK) gene locus.

290

planned